-
Clinical Otolaryngology and Allied... Feb 1989While the origins of sudden sensorineural hearing loss remain unproven and treatment empirical, the most appropriate therapy remains a matter of controversy. In this... (Comparative Study)
Comparative Study
While the origins of sudden sensorineural hearing loss remain unproven and treatment empirical, the most appropriate therapy remains a matter of controversy. In this paper we have analysed the current forms of treatment, i.e. diatrizoate meglumine, steroids and a vasodilator. The results suggest that although several related factors were shown to indicate a good prognosis regardless of the therapy, none of the currently available regimens produces consistently better results than the spontaneous recovery rate of 65% reported by Mattox & Simmons.
Topics: Adult; Audiometry; Betahistine; Diatrizoate Meglumine; Drug Therapy, Combination; Female; Hearing Loss, Sensorineural; Humans; Male; Prednisolone; Pyridines
PubMed: 2920456
DOI: 10.1111/j.1365-2273.1989.tb00336.x -
Investigative Radiology Jan 1992Myocardial ATP, ADP, and AMP were measured from cardiac biopsy in 11 dogs after intracoronary injection of 6 mL of sodium-meglumine diatrizoate (SMD), iohexol (IOH), or... (Comparative Study)
Comparative Study
Myocardial ATP, ADP, and AMP were measured from cardiac biopsy in 11 dogs after intracoronary injection of 6 mL of sodium-meglumine diatrizoate (SMD), iohexol (IOH), or 0.9% sodium chloride (NaCl), and in three of the dogs at baseline before any injection. The ATP at baseline and after SMD, IOH, and 0.9% NaCl were 5.39 +/- 0.41, 3.72 +/- 0.70, 5.52 +/- 0.82, and 5.44 +/- 1.40 mumol/g wet weight, respectively. There were significant differences between SMD and IOH (P less than .02), and between SMD and 0.9% NaCl (P less than .05). The energy charge of SMD was 0.82 +/- 0.08, which differed from 0.89 +/- 0.02 for NaCl or 0.9 +/- 0.05 for baseline (P less than .05), but not from 0.85 +/- 0.04 for IOH. In conclusion, diatrizoate caused significant depletions in ATP stores in comparison with iohexol, but there was no significant difference with respect to energy charge. Nonionic contrast media would be preferable for coronary arteriography in patients whose high-energy stores might be depleted from severe ischemia.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Coronary Vessels; Diatrizoate Meglumine; Dogs; Energy Metabolism; Female; Heart; Hemodynamics; Injections, Intra-Articular; Iohexol; Male; Myocardium
PubMed: 1733878
DOI: No ID Found -
Japanese Journal of Radiology Aug 2023
Topics: Humans; Diatrizoate Meglumine; Off-Label Use; Insurance, Health; Radiologists
PubMed: 36913009
DOI: 10.1007/s11604-023-01404-3 -
Radiology May 1989The effect of diatrizoate on the chronic toxicity of chymopapain in the epidural space was studied. Chymopapain was injected epidurally into four monkeys; chymopapain...
The effect of diatrizoate on the chronic toxicity of chymopapain in the epidural space was studied. Chymopapain was injected epidurally into four monkeys; chymopapain plus diatrizoate meglumine, into four. In 3 months, neither group developed significantly more arachnoiditis than a control group of animals that had received epidural injections of physiologic saline. No synergistic effect of chymopapain and diatrizoate on the meninges was detected.
Topics: Animals; Arachnoiditis; Chymopapain; Diatrizoate Meglumine; Drug Synergism; Injections, Epidural; Macaca fascicularis; Meninges
PubMed: 2704813
DOI: 10.1148/radiology.171.2.2704813 -
PloS One 2022Meconium-related ileus in very low birth weight infants can lead to increased morbidity or mortality and prolonged hospitalization without prompt diagnosis and...
BACKGROUND
Meconium-related ileus in very low birth weight infants can lead to increased morbidity or mortality and prolonged hospitalization without prompt diagnosis and treatment. This study primarily aimed to identify the incidence of and factors associated with meconium-related ileus and secondarily sought to investigate clinical and growth outcomes after water-soluble contrast media (Gastrografin) enema.
METHODS
We retrospectively reviewed medical records of very low birth weight infants born between February 2009 and March 2019 in the neonatal intensive care unit of a single medical center. Perinatal factors, clinical outcomes, and growth outcomes were compared between the group with meconium-related ileus that received Gastrografin enema and the control group.
RESULTS
Twenty-four (6.9%) patients were diagnosed with meconium-related ileus among 347 very low birth weight infants. All achieved successful evacuation of meconium with an average of 2.8 (range: 1-8) Gastrografin enema attempts without procedure-related complications. Initiation of Gastrografin enema was performed at mean 7.0 days (range: 2-16) after birth. Incidences of moderate to severe bronchopulmonary dysplasia were higher and the duration of mechanical ventilation and need for oxygen were longer in the meconium-related ileus group (P = 0.039, 0.046, 0.048, respectively). Meconium-related ileus infants took more time to start enteral feeding and the nothing per oral time was longer (P = 0.001 and 0.018, respectively). However, time to achieve full enteral feeding and Z-scores for weight and height at 37 weeks and at 6 months corrected age did not differ between the two groups.
CONCLUSIONS
Gastrografin enema in very low birth weight infants with meconium-related ileus was an effective and safe medical management. Following Gastrografin enema, very low birth weight infants with meconium-related ileus achieved similar subsequent feeding progress and similar growth levels as the control groups without meconium-related ileus.
Topics: Diatrizoate Meglumine; Enema; Humans; Ileus; Infant, Newborn; Infant, Very Low Birth Weight; Intestinal Obstruction; Meconium; Retrospective Studies
PubMed: 35951504
DOI: 10.1371/journal.pone.0272915 -
AJR. American Journal of Roentgenology Jun 1997
Topics: Administration, Oral; Aged; Aged, 80 and over; Anaphylaxis; Contrast Media; Diatrizoate Meglumine; Female; Humans; Respiratory Insufficiency
PubMed: 9168750
DOI: 10.2214/ajr.168.6.9168750 -
The British Journal of Radiology Aug 1993A new oral formulation of iopamidol, "Gastromiro", was evaluated as a bowel contrast agent during abdominal computed tomography (CT). Comparison was made with the well... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
A new oral formulation of iopamidol, "Gastromiro", was evaluated as a bowel contrast agent during abdominal computed tomography (CT). Comparison was made with the well established agents sodium/meglumine diatrizoate ("Urografin 370") and dilute barium sulphate ("E-Z CAT") in a randomized, blind study of 150 consecutive patients undergoing abdominal and/or pelvic CT. Parameters assessed included quality of bowel opacification, artefact generation, contrast-medium palatibility, side effects and cost. No significant difference was found between the three contrast media in stomach- or small-bowel opacification. E-Z CAT was superior at opacifying the caecum/ascending colon. No compelling reason to choose a particular agent was found in the other assessed parameters, but cost is a significant factor.
Topics: Administration, Oral; Artifacts; Barium Sulfate; Costs and Cost Analysis; Diatrizoate Meglumine; Digestive System; Evaluation Studies as Topic; Humans; Iopamidol; Observer Variation; Tomography, X-Ray Computed
PubMed: 7719680
DOI: 10.1259/0007-1285-66-788-681 -
Veterinary Medicine, Small Animal... Sep 1981
Topics: Animals; Cats; Diatrizoate; Diatrizoate Meglumine; Dogs; Drug Evaluation; Radiography
PubMed: 6916550
DOI: No ID Found -
Surgery Jul 2017
Topics: Adhesives; Contrast Media; Diatrizoate Meglumine; Humans; Intestinal Obstruction; Intestine, Small; Tissue Adhesions
PubMed: 28256258
DOI: 10.1016/j.surg.2017.01.017 -
AJR. American Journal of Roentgenology Mar 2003This study was designed to assess whether gastrointestinal administration of iodinated contrast media results in peripheral blood eosinophilia.
OBJECTIVE
This study was designed to assess whether gastrointestinal administration of iodinated contrast media results in peripheral blood eosinophilia.
MATERIALS AND METHODS
We studied 110 patients in a retrospective review. Diatrizoate meglumine and diatrizoate sodium for abdominal CT were administered to 98 of these patients; 22 of the 98 had also been given the same contrast medium administered by enema. The remaining 12 patients were given diatrizoate sodium for gastrointestinal fluoroscopy. A control group of 65 patients underwent single-contrast barium upper gastrointestinal or enema examinations. WBC and eosinophil counts were determined approximately 24 hr before the examination and every 24 hr thereafter, through the ninth day.
RESULTS
Eosinophilia was detected in 17 (15.5%) of 110 patients after gastrointestinal administration of iodinated contrast media. The prevalence of eosinophilia after administration of iodinated contrast media was statistically significantly different compared with that in the control group, in which none of the 65 patients had eosinophilia (p < 0.001). Eosinophilia was detected 48 hr after application of iodinated contrast agents and lasted through the sixth day, with a peak on the fifth day. The prevalence of eosinophilia was independent of route of application, dose, or type of iodinated contrast medium. Eosinophilia in all cases was clinically asymptomatic.
CONCLUSION
Eosinophilia that is caused by gastrointestinal administration of iodinated contrast media is a transient, clinically silent phenomenon. It may lead to unnecessary workup for known conditions associated with eosinophilia.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Aged; Aged, 80 and over; Blood; Contrast Media; Diatrizoate; Diatrizoate Meglumine; Eosinophilia; Female; Humans; Male; Middle Aged; Retrospective Studies
PubMed: 12591690
DOI: 10.2214/ajr.180.3.1800751